Aclaris Therapeutics Inc (NASDAQ: ACRS) on Friday, plunged -12.04% from the previous trading day, before settling in for the closing price of $4.32. Within the past 52 weeks, ACRS’s price has moved between $0.77 and $5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 74.29%. The company achieved an average annual earnings per share of 41.73%. With a float of $67.90 million, this company’s outstanding shares have now reached $70.89 million.
The extent of productivity of a business whose workforce counts for 91 workers is very important to gauge. In terms of profitability, gross margin is 53.53%, operating margin of -150.31%, and the pretax margin is -138.0%.
Aclaris Therapeutics Inc (ACRS) Insider Updates
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Aclaris Therapeutics Inc is 4.01%, while institutional ownership is 70.03%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares. Before that another transaction happened on Aug 05 ’24, when Company’s 10% Owner bought 206,025 for $1.24, making the entire transaction worth $256,357. This insider now owns 14,250,000 shares in total.
Aclaris Therapeutics Inc (ACRS) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.02 earnings per share (EPS) for the period topping the consensus outlook (set at -0.39) by 0.37. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.73% per share during the next fiscal year.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Aclaris Therapeutics Inc (ACRS) is currently performing well based on its current performance indicators. A quick ratio of 7.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.52, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
The latest stats from [Aclaris Therapeutics Inc, ACRS] show that its last 5-days average volume of 19.78 million was superior to 1.41 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 63.59%. Additionally, its Average True Range was 0.48.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 66.17%, which indicates a significant increase from 56.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 260.92% in the past 14 days, which was higher than the 116.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.77, while its 200-day Moving Average is $1.35. Now, the first resistance to watch is $4.23. This is followed by the second major resistance level at $4.65. The third major resistance level sits at $4.87. If the price goes on to break the first support level at $3.59, it is likely to go to the next support level at $3.37. Assuming the price breaks the second support level, the third support level stands at $2.95.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
Market capitalization of the company is 238.77 million based on 71,431K outstanding shares. Right now, sales total 31,250 K and income totals -88,480 K. The company made 4,350 K in profit during its latest quarter, and -7,590 K in sales during its previous quarter.
